Closed Loop Medicine has been granted US patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health. 

The company currently holds over 65 filings across 16 patent families.  

In the rapidly-established GLP-1 market, the company’s IP covers dose optimisation according to patient-specific factors such as degree of calorie restriction or exercise, providing an opportunity for the development of personalised co-therapies enhancing existing GLP-1 medicines. 

The latest patent granted by the US Patent Office extends Closed Loop Medicine’s cardiometabolic capabilities into DOAC therapy, enabling more personalised and potentially more effective anticoagulation treatment.  

This patent supports AI-powered precision dosing for patients requiring DOACs, which the company says will improve safety and efficacy in stroke prevention and other cardiovascular conditions. 

Dr Hakim Yadi OBE, CEO and Co-founder of Closed Loop Medicine, says: “Establishing a strong and differentiated patent portfolio is central to our leadership in AI-enabled personalised medicine. These patents reinforce our ability to deliver smarter, AI-enabled pharmacometric dosing solutions. Not only to improve clinical outcomes and optimise treatment for cardiometabolic diseases with novel drug forms, but also software enhancements of existing drugs, the latter receiving timely support with the FDA’s recent Prescription Drug Use-Related Software PDURS guidance.”

Diana Spencer, Senior Digital Content Editor, DDW